Variants of uncertain significance in the genetic diagnosis of heterozygous familial hypercholesterolemia

Background. Studying the genetic profile of patients with familial hypercholesterolemia (FH) and their phenotypic characteristics may contribute to a better understanding of the pathogenesis of the disease.
Objective. Evaluation of the genetic profile of patients with severe FH phenotype and study of the phenotype of patients with variants of uncertain significance.
Design and methods. The study included patients over 18 years of age with ≥ 7 points on the Dutch Lipid Clinical Network Criteria (DLCN) score from the register of the Centre for Atherosclerosis and Lipid Metabolism Disorders of the Almazov National Medical Research Centre. Clinical and anamnestic data were collected, and molecular genetic testing was performed to identify variants in candidate genes responsible for the development of FH.
Results. Of 127 patients (mean age 45,2 ± 12,8 years, 61,6 % women), molecular genetic analysis identified a positive diagnosis of FH in 61,4 % with a predominant presence of pathogenic variants in the LDLR gene (90,6 %) and the most frequent type II c.1202T>A p.Leu401His. Among patients with variants of uncertain significance (18,1 %) tendon xanthomas and lipoid arc of the cornea were detected in 6,7 % and 20,0 %, respectively. The mean LDL–C level before treatment was 7,7 ± 1,7 mmol/L. Variants of uncertain significance were verified mainly in low-density lipoprotein cholesterol (35,9 %) and APOB (28,2 %) genes. Three patients from the study sample are carriers of variants in two FH genes: c.*653G>A in LDLR with c.11788+16C>T in APOB; c.1465T>A in LDLR with c.*25C>T in APOE; c.817+6C>T in LDLR with c.2068–4T>A in APOB.
Conclusions. The genetic profile of patients with FH is represented by various mutation variants in a number of known genes, the presence of variants of uncertain significance in LDLR and APOB genes indicates the complex genetic nature of the disease, indicating the need for further study of their role.

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490a. doi:10.1093/eurheartj/eht273

2. Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277–2291. doi:10.1093/eurheartj/ehad197

3. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV et al. International Familial Hypercholesterolemia Foundation. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015;22(7):849–854. doi:10.1177/2047487314533218

4. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med. 2004;4(1): 59–65. doi:10.1055/s-2004-822987

5. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991;303(6807):893–896. doi:10.1136/bmj.303.6807.893

6. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S9–S17. doi:10.1016/j.jacl.2011.03.452

7. Meriño-Ibarra E, Castillo S, Mozas P, Cenarro A, Martorell E, Díaz JL et al. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Biol. 2005;77(5):663–673. doi:10.1353/hub.2006.0005

8. Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H et al. Homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2021;28(7):665–678. doi:10.5551/jat.RV17050

9. Palacios L, Grandoso L, Cuevas N, Olano-Martín E, Martinez A, Tejedor D et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis. 2012;221(1):137– 142. doi:10.1016/j.atherosclerosis.2011.12.021

10. Olmastroni E, Gazzotti M, Averna M, Arca M, Tarugi P, Calandra S et al. Lipoprotein(a) genotype influences the clinical diagnosis of familial hypercholesterolemia. J Am Heart Assoc. 2023;12(10):e029223. doi:10.1161/JAHA.122.029223

11. Tada H, Kojima N, Yamagami K, Nomura A, Nohara A, Usui S et al. Impact of variants of uncertain significance of LDL receptor on phenotypes of familial hypercholesterolemia. J Clin Lipidol. 2022;16(6):863–869. doi:10.1016/j.jacl.2022.09.007

12. Olmastroni E, Gazzotti M, Arca M, Averna M, Pirillo A, Catapano AL et al. Twelve variants polygenic score for low-density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with or without causative mutations. J Am Heart Assoc. 2022;11(7):e023668. doi:10.1161/JAHA.121.023668

13. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013; 381(9874):1293–301. doi:10.1016/S0140-6736(12)62127-8

14. Miserez AR, Schuster H, Chiodetti N, Keller U. Polymorphic haplotypes and recombination rates at the LDL receptor gene locus in subjects with and without familial hypercholesterolemia who are from different populations. Am J Hum Genet. 1993;52(4):808–826.

15. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–713. doi:10.1038/nature09270

16. Di Costanzo A, Minicocci I, D’Erasmo L, Commodari D, Covino S, Bini S et al. Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. J Clin Lipidol. 2021;15(6):822–831. doi:10.1016/j.jacl.2021.10.001

17. Alieva AS, Tokgözoğlu L, Ray KK, Catapano AL. Lipid Clinics Network. Rationale and design of the EAS global project. Atheroscler Suppl. 2020;42:e6‑e8. doi:10.1016/j.atherosclerosissup.2021.01.002

18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30

19. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–569. doi:10.1002/humu.22981

20. Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S et al. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler Suppl. 2017;29:17–24. doi:10.1016/j.atherosclerosissup.2017.07.002

21. Chora JR, Medeiros AM, Alves AC, Bourbon M. Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. Genet Med. 2018;20(6):591–598. doi:10.1038/gim.2017.151

22. Kusters DM, Huijgen R, Defesche JC, Vissers MN, Kindt I, Hutten BA et al. Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes. Neth Heart J. 2011;19(4):175–182. doi:10.1007/s12471-011-0076-6

23. Santos RD, Bourbon M, Alonso R, Cuevas A, Vasques-Cardenas NA, Pereira AC et al. Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. J Clin Lipidol. 2017;11(1):160–166. doi:10.1016/j.jacl.2016.11.004

24. Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 2008;200(2):315–321. doi:10.1016/j.atherosclerosis.2007.12.024

25. Meshkov AN, Ershova AI, Kiseleva AV, Shalnova SA, Drapkina OM, Boytsov SA. The Prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian Federation: the FH-ESSE-RF study. J Pers Med. 2021;11(6):464. doi:10.3390/jpm11060464

26. Leigh S, Futema M, Whittall R, Taylor-Beadling A, Williams M, den Dunnen JT et al. The UCL low-density lipoprotein receptor gene variant database: pathogenicity update. J Med Genet. 2017;54(4):217–223. doi:10.1136/jmedgenet-2016-104054

27. Futema M, Ramaswami U, Tichy L, Bogsrud MP, Holven KB, Roeters van Lennep J et al. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2021;319:108–117. doi:10.1016/j.atherosclerosis.2021.01.008

28. Kindt I, Mata P, Knowles JW. The role of registries and genetic databases in familial hypercholesterolemia. Curr Opin Lipidol. 2017;28(2):152–160. doi:10.1097/MOL.0000000000000398

29. Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019;16(1):9–20. doi:10.1038/s41569-018-0052-6

30. Gazzotti M, Casula M, Olmastroni E, Averna M, Arca M, Catapano AL. How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. Atheroscler Suppl. 2020;42:e35‑e40. doi:10.1016/j.atherosclerosissup.2021.01.007

31. Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterolaemia studies collaboration. Atheroscler Suppl. 2016;22:1–32. doi:10.1016/j.atherosclerosissup.2016.10.001